Mammary tumor development in dogs is associated with BRCA1 and BRCA2

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8770-8774

  Rivera, Patricio J ^a   Melin, Malin ^b   Biagi, Tara ^d   Fall, Tove ^a   Häggström, Jens ^a   Lindblad Toh, Kerstin ^c,d   Von Euler, Henrik ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; ONCOPROTEIN; PROTEIN LSP1; PROTEIN P53; PROTEIN RCAS1; PROTEIN TOX3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; EXPERIMENTAL DOG; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BREAST NEOPLASMS; DOGS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 72249098717     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1725     Document Type: Article

References (49)

1. Egenvall A, Bonnett BN, Ohagen P, Olson P, Hedhammar A, von Euler H. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Prev Vet Med 2005;69:109-127
2. Fidler IJ, Brodey RS. The biological behavior of canine mammary neoplasms. J Am Vet Med Assoc 1967;151: 1311-1318
3. Priester WA, Mantel N. Occurrence of tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 1971;47:1333-1344
4. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California: II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40:307-318
5. Moe L. Population-based incidence of mammary tumours in some dog breeds. J Reprod Fertil Suppl 2001; 57:439-443
6. Moulton JE, Rosenblatt LS, Goldman M. Mammary tumors in a colony of beagle dogs. Vet Pathol 1986; 23:741-749
7. Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI, Black MM. Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 1983;20:127-142
8. Moulton JE, Taylor DO, Dorn CR, Andersen AC. Canine mammary tumors. Vet Pathol 1970;7:289-320.
9. Cohen D, Reif JS, Brodey RS, Keiser H. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 1974;34:2859-2868
10. In: Cotran R, Kumar V, Robbins SL, Schoen FJ, editors. Pathologic Basis of Disease. 5th ed Philadelphia: WB Saunders; 1994.
11. Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 1969;43:1249-1261
12. Chrisp CE, Spangler WL. The malignant canine mammary tumor as a model for the study of human breast cancer. In: Shifrine M, Wilson FD, editors. The Canine as a Biomedical ResearchModel: Immunological, Hematological and Oncological Aspects. Oak Ridge (TN): Technical Information Center/U.S. Department of Energy (Dist. by National Technical Information Service/U.S. Department of Commerce, Springfield, VA); 1980. p. 331-349
13. Frese K. [Comparative pathology of breast tumors in domestic animals]. VerhDtsch Ges Pathol 1985;69: 152-170
14. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-689 (Pubitemid 28164626)
15. King MC, Marks JH, Mandell JB, New York Breast Canc Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646
16. Antoniou AC, Pharoah PDP, Easton DF, Evans DG. BRCA1 and BRCA2 cancer risks. J Clin Oncol 2006;24: 3312-3313
17. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated withspecific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336: 1401-1408
18. CouchFJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat 1996;8:8-18.
19. WalshT, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295: 1379-1388
20. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13qlinked kindreds. Nat Genet 1996;12:333-337 (Pubitemid 26080098)
21. Casilli F, Tournier I, Sinilnikova OM, et al. The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet 2006;43:e49.
22. Easton DF, Pooley KA, Dunning AM, et al. Genomewide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-U7.
23. Hofstra RM, Spurdle AB, Eccles D, et al. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat 2008;29:1292-1303
24. WalshT , King MC. Ten genes for inherited breast cancer. Cancer Cell 2007;11:103-105 (Pubitemid 46209856)
25. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4:850-860 (Pubitemid 39472952)
26. Rousseau J, Tetu B, Caron D, et al. RCAS1 is associated withduct al breast cancer progression. Biochem Biophys Res Commun 2002;293:PII S0006-291X(02) 00401-411
27. Meijers-Heijboer H, Wijnen J, Vasen H, et al. The CHEK2 1100delC mutation identifies families witha hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003;72:1308-1314 (Pubitemid 36530019)
28. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-59 (Pubitemid 34887638)
29. Sutter NB, Eberle MA, Parker HG, et al. Extensive and breed-specific linkage disequilibrium in Canis familiaris. Genome Res 2004;14:2388-2396
30. Lindblad-TohK, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005;438:803-819 (Pubitemid 41753059)
31. Kruglyak L. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet 1999;22:139-144 (Pubitemid 29264806)
32. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-861
33. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575 (Pubitemid 47330214)
34. Bonferroni CE, . Il calcolo delle assicurazioni su gruppi di teste. In Studi in Onore del Professore Salvatore Ortu Carboni. Rome: Italy 1935; p. 13-60.
35. Bonferroni CE. Teoria delle classi e calcolo e Comreciali di Firenze 1936;8, 3-62.
36. Ochiai K, Morimatsu M, Tomizawa N, Syuto B. Cloning and sequencing full lengthof canine Brca2 and Rad51 cDNA. J Vet Med Sci 2001;63:1103-1108
37. Martin AM, Greshock JD, Rebbeck TR, Weber BL. Allele frequencies of cytokine gene polymorphisms in Caucasians and African Americans. Am J Hum Genet 2000;67:1760.
38. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated withrisk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-874 (Pubitemid 47014500)
39. Tapper W, Hammond V, Gerty S, et al. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 2008;10:R108.
40. Udler MS, Meyer KB, Pooley KA, et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet 2009;18:1692-1703
41. Crook T, Brooks LA, Crossland S, et al. p53 mutation withfrequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998;17:1681-1689 (Pubitemid 28482645)
42. Gretarsdottir S, Thorlacius S, Valgardsdottir R, et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998;58:859-862
43. Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol 1999;17:3653-3663
44. Phillips HA. The role of the p53 tumour suppressor gene in human breast cancer. Clin Oncol (R Coll Radiol) 1999;11:148-155 (Pubitemid 29366585)
45. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat 2003;21:301-306 (Pubitemid 36292972)
46. Majdak-Paredes EJ, FatahF. Hereditary breast cancer syndromes and clinical implications. J Plast Reconstr Aesthet Surg 2009;62:181-189
47. Nieto A, Perez-Alenza MD, Del Castillo N, Tabanera E, Castano M, Pena L. BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables. J Comp Pathol 2003;128:260-268 (Pubitemid 36531661)
48. Dupont WD, Parl FF, Hartmann WH, et al. Breastcancer risk associated withproliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-1265
49. Worsham MJ, Pals G, Raju U, Wolman SR. Establishing a molecular continuum in breast cancer: DNA microarrays and benign breast disease. Cytometry 2002;47: 56-59 (Pubitemid 34032582)